Search Within

Advanced Practice Providers

  1. "Craig Moskowitz"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (10)
Groups
  1. Department of Medicine (27)
  2. Hematologic Malignancies, Division of (27)
  3. Center for Hematologic Malignancies (25)
  4. Lymphoma (24)
  5. Survivorship Research (23)
  6. Nursing (22)

More Groups

People
  1. Craig Moskowitz (27)
  2. Andrew Zelenetz (21)
  3. Matthew Matasar (20)
  4. Alison Moskowitz (18)
  5. John Gerecitano (17)
  6. Ariela Noy (16)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2019 (1)
  4. 2018 (2)
  5. 2017 (4)
  6. 2016 (3)

More Years

Publications
  1. Blood (11)
  2. Journal of Clinical Oncology (5)
  3. Annals of Oncology (3)
  4. Biology of Blood and Marrow Transplantation (2)
  5. Hematological Oncology (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (3)
  4. Oxford University Press (3)
  5. Wiley Blackwell (2)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (27)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Haematologica (2016)

    Fulltext@MSK | Save
  • Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
    Journal Article

    Shah, G. L.; Yahalom, J.; Matasar, M. J.; Verwys, S. L.; Goldman, D. A.; Bantilan, K. S.; Zhang, Z.; McCall, S. J.; Moskowitz, A. J.; Moskowitz, C. H.
    British Journal of Haematology (2016)

    Fulltext@MSK | Save
  • Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Yahalom, J.; Schöder, H.; Barr, P. M.; Caron, P.; Chiu, A.; Constine, L. S.; Drullinsky, P.; Friedberg, J. W.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Risk factors predicting outcomes for primary refractory Hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Bantilan, K. S.; Verwys, S. L.; McCall, S. J.; Yahalom, J.; Matasar, M. J.; Moskowitz, A. J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • TARC predicts PET-normalization and event free surival in relapsed/refractory Hodgkin lymphoma patients treated with brentuximab vedotin
    Meeting Abstract

    Moskowitz, A. J.; Cho, S.; Fleisher, M.; Woo, K. M.; Zhang, Z. G.; Fox, S.; McCall, S. J.; Schoder, H.; Yahalom, J.; Moskowitz, C. H.
    Blood (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: A non-randomised, open-label, single-centre, phase 2 study
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Yahalom, J.; Mccall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Safety and early efficacy in an ongoing pilot study of brentuximab vedotin and AVD chemotherapy followed by 30 gray involved-site radiotherapy for newly diagnosed, early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Yahalom, J.; Schoder, H.; Caron, P.; Drullinsky, P.; Gerecitano, J. F.; Hamilton, A.; Hamlin, P.; Horwitz, S. M.; Jacob, A. G.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • ABT-888 plus bendamustine is safe and has shown preliminary efficacy in patients with lymphoma
    Meeting Abstract

    Gerecitano, J. F.; Schwartz, G. K.; Carvajal, R.; Fury, M.; Konner, J.; Hyman, D. M.; Gounder, M.; Gajria, D.; Teitcher, J.; Zhang, Z.; more...
    Blood (2013)

    Fulltext@MSK | Save